Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026
Rhea-AI Summary
Upstream Bio (Nasdaq: UPB) will present additional efficacy data from the Phase 2 VIBRANT trial of verekitug in chronic rhinosinusitis with nasal polyps (CRSwNP) at the EAACI 2026 Congress in Istanbul on June 14, 2026.
The oral session will highlight a responder analysis of clinically meaningful improvements in key disease measures. Verekitug is described as the only known TSLP receptor antagonist currently in clinical development.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
UPB fell 5.11% with several biotech peers also down: SYRE -5.3%, QURE -4.27%, RAPP -2.83%, while TRML was flat and VERV was roughly unchanged at -0.09%, suggesting broader sector pressure alongside the company-specific clinical update.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 18 | Phase 2 data update | Positive | -6.4% | New VIBRANT data in CRSwNP with comorbid asthma showing symptom and steroid-sparing benefits. |
| Apr 17 | Conference presentation | Neutral | -1.1% | Announcement of upcoming VIBRANT CRSwNP data posters at ATS 2026 focused on biomarkers and outcomes. |
| Feb 26 | Additional trial analyses | Positive | +2.1% | Plan to present additional VIBRANT efficacy and safety analyses at AAAAI 2026 late-breaking session. |
| Feb 11 | Top-line Phase 2 asthma | Positive | -47.2% | Positive VALIANT asthma results with significant AAER reductions and lung function gains for verekitug. |
| Sep 02 | Top-line Phase 2 CRSwNP | Positive | +18.3% | VIBRANT CRSwNP met primary endpoint with strong nasal polyp and symptom improvements and favorable safety. |
Clinical trial news has often coincided with negative or mixed price reactions, with an average move of -6.86% across recent clinical updates and multiple instances where positive data were followed by share price declines.
Over the past year, Upstream Bio has repeatedly highlighted verekitug’s progress in severe asthma and CRSwNP. Positive Phase 2 VIBRANT and VALIANT data, including statistically significant efficacy and biomarker improvements, were followed by plans to start Phase 3 trials in Q1 2027. Several clinical-data presentations at conferences (AAAAI, ATS) have produced mixed market reactions, including one selloff of 47.18% despite favorable results. Today’s EAACI efficacy-responder analysis fits this pattern of ongoing Phase 2 data refinement ahead of Phase 3 planning.
Historical Comparison
Across five prior clinical-trial updates, UPB’s average move was -6.86%, with several declines on positive data. Today’s Phase 2 VIBRANT responder-analysis news and the -5.11% move fit that historically cautious reaction profile.
Clinical-trial news has tracked verekitug from positive top-line Phase 2 VIBRANT and VALIANT results through multiple additional analyses and conference presentations, building a data package that supports planned Phase 3 programs in severe asthma and CRSwNP targeted for Q1 2027 initiation.
Market Pulse Summary
This announcement adds a responder-analysis layer to prior Phase 2 VIBRANT results in CRSwNP, focusing on clinically meaningful improvements in disease measures with verekitug. It follows multiple conference presentations and positive top-line data that supported moving into Phase 3 in severe asthma and CRSwNP in Q1 2027. Investors may weigh this incremental efficacy detail against regulatory disclosures, the $150,000,000 ATM capacity, ongoing net losses of $40.6 million per quarter, and a cash position of $294.6 million funding development plans.
Key Terms
phase 2 medical
chronic rhinosinusitis with nasal polyps medical
responder analysis medical
thymic stromal lymphopoietin medical
biologics medical
AI-generated analysis. Not financial advice.
WALTHAM, Mass., June 08, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that additional data from its Phase 2 VIBRANT trial of verekitug in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) will be presented in an oral session at the European Academy of Allergy and Clinical Immunology (EAACI) 2026 Congress in Istanbul, Turkey, on Sunday, June 14, 2026. The presentation will feature a responder analysis examining the proportion of patients who achieved clinically meaningful improvements in key measures of disease with verekitug. Verekitug is the only known antagonist of the thymic stromal lymphopoietin (TSLP) receptor currently in clinical development.
Presentation details:
Presentation Title: Verekitug, a novel TSLP receptor antagonist antibody, in participants with chronic rhinosinusitis with nasal polyps in VIBRANT: responder analysis using clinically meaningful efficacy outcome thresholds
Presenting Author: Joaquim Mullol, MD, PhD, Universitat de Barcelona
Session: OAS23 - Transforming disease course: clinical outcomes and remission with biologics
Presentation Date and Time: Sunday, June 14, 2026 – 15:15 – 16:45 TRT
Location: Room Munich
About Verekitug
Verekitug is a novel recombinant fully human immunoglobulin G1 (IgG1) monoclonal antibody that binds to the thymic stromal lymphopoietin (TSLP) receptor and inhibits proinflammatory signaling initiated by TSLP. It is the only known antagonist currently in clinical development that targets and inhibits the TSLP receptor.
TSLP is a cytokine that is a key driver of the inflammatory response in major allergic and inflammatory diseases, such as asthma, where disruption of TSLP signaling has been clinically validated as an effective therapeutic strategy. TSLP activation is one of the first events in the inflammatory cascade stimulated by allergens, viruses and other triggers, initiating the activation of downstream targets such as IL-4, IL-5, IL-13, IL-17 and IgE. Because TSLP is a target upstream in the inflammatory cascade, blocking the TSLP receptor presents an opportunity for a single treatment to impact the drivers of multiple pathological inflammatory processes across a broad set of diseases.
Verekitug has advanced into three separate global, placebo-controlled, randomized Phase 2 clinical trials including the recently completed positive VIBRANT trial (NCT06164704) in patients with CRSwNP and VALIANT trial (NCT06196879) in patients with severe asthma. The VENTURE trial (NCT06981078) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) is ongoing. Additionally, in May 2025, Upstream Bio initiated the VALOUR trial (NCT06966479), a long-term extension study in eligible participants with severe asthma who completed the VALIANT Phase 2 clinical trial.
About Upstream Bio
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets and inhibits the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. The Company has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and chronic obstructive pulmonary disease (COPD). Upstream Bio’s team is committed to maximizing verekitug’s unique attributes to address the substantial unmet needs for patients underserved by today’s standard of care. To learn more, please visit www.upstreambio.com.
Investor and Media Contact:
Meggan Buckwell
Director, Corporate Communications and Investor Relations
ir@upstreambio.com
